Advanced search
Publication Cover
Expert Review of Vaccines Volume 11, 2012 - Issue 5
Submit an article Journal homepage
259
Views
22
CrossRef citations to date
0
Altmetric
Vaccine Profile

MenACWY-TT vaccine for active immunization against invasive meningococcal disease

Vassiliki Papaevangelou National and Kapodistrian University of Athens Medical School, Athens University, Goudi 11527, Athens, Greece. [email protected]
&
Nikos Spyridis National and Kapodistrian University of Athens Medical School, Athens University, Goudi 11527, Athens, Greece. [email protected]
Pages 523-537 | Published online: 09 Jan 2014

References

  • Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N. Engl. J. Med. 344(18), 1378–1388 (2001).
  • Tan LK, Carlone GM, Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N. Engl. J. Med. 362(16), 1511–1520 (2010).
  • Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 27(Suppl. 2), B51–B63 (2009).
  • Gardner P. Clinical practice. Prevention of meningococcal disease. N. Engl. J. Med. 355(14), 1466–1473 (2006).
  • Caugant DA, Tzanakaki G, Kriz P. Lessons from meningococcal carriage studies. FEMS Microbiol. Rev. 31(1), 52–63 (2007).
  • Greenwood B. Editorial: 100 years of epidemic meningitis in West Africa – has anything changed? Trop. Med. Int. Health 11(6), 773–780 (2006).
  • Fellick JM, Sills JA, Marzouk O, Hart CA, Cooke RW, Thomson AP. Neurodevelopmental outcome in meningococcal disease: a case–control study. Arch. Dis. Child. 85(1), 6–11 (2001).
  • Erickson LJ, De Wals P, McMahon J, Heim S. Complications of meningococcal disease in college students. Clin. Infect. Dis. 33(5), 737–739 (2001).
  • Kaplan SL, Schutze GE, Leake JA et al. Multicenter surveillance of invasive meningococcal infections in children. Pediatrics 118(4), e979–e984 (2006).
  • Poland GA. Prevention of meningococcal disease: current use of polysaccharide and conjugate vaccines. Clin. Infect. Dis. 50(Suppl. 2), S45–S53 (2010).
  • Maiden MC, Ibarz-Pavón AB, Urwin R et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J. Infect. Dis. 197(5), 737–743 (2008).
  • Bettinger JA, Scheifele DW, Le Saux N, Halperin SA, Vaudry W, Tsang R; Canadian Immunization Monitoring Program, Active (IMPACT). The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada. Pediatr. Infect. Dis. J. 28(3), 220–224 (2009).
  • Simpkins D, Wood N, Jelfs J et al. Modern trends in mortality from meningococcal disease in Australia. Pediatr. Infect. Dis. J. 28(12), 1119–1120 (2009).
  • Macneil JR, Cohn AC, Zell ER et al.; Active Bacterial Core surveillance (ABCs) Team and MeningNet Surveillance Partners. Early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine. Pediatr. Infect. Dis. J. 30(6), 451–455 (2011).
  • Harrison LH, Pelton SI, Wilder-Smith A et al. The Global Meningococcal Initiative: recommendations for reducing the global burden of meningococcal disease. Vaccine 29(18), 3363–3371 (2011).
  • Epidemics of meningococcal disease. African meningitis belt, 2001. Wkly Epidemiol. Rec. 76(37), 282–288 (2001).
  • Greenwood BM, Bradley AK, Cleland PG et al. An epidemic of meningococcal infection at Zaria, Northern Nigeria. 1. General epidemiological features. Trans. R Soc. Trop. Med. Hyg. 73(5), 557–562 (1979).
  • Irving TJ, Blyuss KB, Colijn C, Trotter CL. Modelling meningococcal meningitis in the African meningitis belt. Epidemiol. Infect. 1–9 (2011).
  • Enhanced surveillance of invasive meningococcal disease in Canada: 1 January, 2004, through 31 December, 2005. Can. Commun. Dis. Rep. 33(10), 1–15 (2007).
  • Harrison LH, Kreiner CJ, Shutt KA et al.; Meningococcal High School Study Group. Risk factors for meningococcal disease in students in grades 9–12. Pediatr. Infect. Dis. J. 27(3), 193–199 (2008).
  • MacLennan J, Kafatos G, Neal K et al.; United Kingdom Meningococcal Carriage Group. Social behavior and meningococcal carriage in British teenagers. Emerging Infect. Dis. 12(6), 950–957 (2006).
  • Olyhoek T, Crowe BA, Achtman M. Clonal population structure of Neisseria meningitidis serogroup A isolated from epidemics and pandemics between 1915 and 1983. Rev. Infect. Dis. 9(4), 665–692 (1987).
  • Harrison LH. Prospects for vaccine prevention of meningococcal infection. Clin. Microbiol. Rev. 19(1), 142–164 (2006).
  • Vogel U, Claus H, Frosch M. Rapid serogroup switching in Neisseria meningitidis. N. Engl. J. Med. 342(3), 219–220 (2000).
  • Linz B, Schenker M, Zhu P, Achtman M. Frequent interspecific genetic exchange between commensal Neisseriae and Neisseria meningitidis. Mol. Microbiol. 36(5), 1049–1058 (2000).
  • Mölling P, Bäckman A, Olcén P, Fredlund H. Comparison of serogroup W-135 meningococci isolated in Sweden during a 23-year period and those associated with a recent hajj pilgrimage. J. Clin. Microbiol. 39(7), 2695–2699 (2001).
  • Mayer LW, Reeves MW, Al-Hamdan N et al. Outbreak of W135 meningococcal disease in 2000: not emergence of a new W135 strain but clonal expansion within the electrophoretic type-37 complex. J. Infect. Dis. 185(11), 1596–1605 (2002).
  • Borrow R, Findlow J. Prevention of meningococcal serogroup C disease by NeisVac-C. Expert Rev. Vaccines 8(3), 265–279 (2009).
  • Ibarz-Pavón AB, Maclennan J, Andrews NJ et al. Changes in serogroup and genotype prevalence among carried meningococci in the United Kingdom during vaccine implementation. J. Infect. Dis. 204(7), 1046–1053 (2011).
  • Ramsay ME, Andrews N, Kaczmarski EB, Miller E. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 357(9251), 195–196 (2001).
  • Boisier P, Nicolas P, Djibo S et al. Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin. Infect. Dis. 44(5), 657–663 (2007).
  • Achtman M. Global epidemiology of meningococcal disease. In: Meningococcal Disease. Cartwright K (Ed.). Wiley, NY, USA, 159–176 (1995).
  • Coulson GB, von Gottberg A, du Plessis M, Smith AM, de Gouveia L, Klugman KP; Group for Enteric, Respiratory and Meningeal Disease Surveillance in South Africa. Meningococcal disease in South Africa, 1999–2002. Emerging Infect. Dis. 13(2), 273–281 (2007).
  • Tapsall J; Australian Meningococcal Surveillance Programme. Annual report of the Australian Meningococcal Surveillance Programme, 2007. Commun. Dis. Intell. 32(3), 299–307 (2008).
  • O’Hallahan J, Lennon D, Oster P et al. From secondary prevention to primary prevention: a unique strategy that gives hope to a country ravaged by meningococcal disease. Vaccine 23(17–18), 2197–2201 (2005).
  • Galloway Y, Stehr-Green P, McNicholas A, O’Hallahan J. Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years. Int. J. Epidemiol. 38(2), 413–418 (2009).
  • Holst J, Martin D, Arnold R et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 27(Suppl. 2), B3–B12 (2009).
  • CDC. Updated recommendations for use of meningococcal conjugate vaccines – Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly Rep. 60(3), 72–76 (2010).
  • Law DK, Lorange M, Ringuette L et al. Invasive meningococcal disease in Quebec, Canada, due to an emerging clone of ST-269 serogroup B meningococci with serotype antigen 17 and serosubtype antigen P1.19 (B:17:P1.19). J. Clin. Microbiol. 44(8), 2743–2749 (2006).
  • Tsang RS, Squires SG, Zollinger WD, Ashton FE. Distribution of serogroups of Neisseria meningitidis and antigenic characterization of serogroup Y meningococci in Canada, January 1, 1999 to June 30, 2001. Can. J. Infect. Dis. 13(6), 391–396 (2002).
  • Gabastou JM, Agudelo CI, Brandileone MC, Castañeda E, de Lemos AP, Di Fabio JL; Grupo de Laboratorio de SIREVA II. [Characterization of invasive isolates of S. pneumoniae, H. influenzae, and N. meningitidis in Latin America and the Caribbean: SIREVA II, 2000–2005]. Rev. Panam. Salud Publica 24(1), 1–15 (2008).
  • Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect. Dis. 10(12), 853–861 (2010).
  • Claus H, Maiden MC, Wilson DJ et al. Genetic analysis of meningococci carried by children and young adults. J. Infect. Dis. 191(8), 1263–1271 (2005).
  • Ala’aldeen DA, Oldfield NJ, Bidmos FA et al. Carriage of meningococci by university students, United Kingdom. Emerging Infect. Dis. 17(9), 1762–1763 (2011).
  • Edwards EA, Devine LF, Sengbusch GH, Ward HW. Immunological investigations of meningococcal disease. III. Brevity of group C acquisition prior to disease occurrence. Scand. J. Infect. Dis. 9(2), 105–110 (1977).
  • De Wals P, Gilquin C, De Maeyer S. [Methods for analyzing the frequency, prevalence and the duration of asymptomatic carriage of Neisseria meningitidis. Longitudinal study of a school population in Belgium]. Med. Trop. (Mars) 42(5), 537–543 (1982).
  • Trotter CL, Greenwood BM. Meningococcal carriage in the African meningitis belt. Lancet Infect. Dis. 7(12), 797–803 (2007).
  • Trotter CL, Gay NJ, Edmunds WJ. The natural history of meningococcal carriage and disease. Epidemiol. Infect. 134(3), 556–566 (2006).
  • Cooper B, DeTora L, Stoddard J. Menveo®: a novel quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135 and Y. Expert Rev. Vaccines 10(1), 21–33 (2011).
  • Harrison LH. Epidemiological profile of meningococcal disease in the United States. Clin. Infect. Dis. 50(Suppl. 2), S37–S44 (2010).
  • Honish L, Soskolne CL, Senthilselvan A, Houston S. Modifiable risk factors for invasive meningococcal disease during an Edmonton, Alberta outbreak, 1999–2002. Can. J. Public Health. 99(1), 46–51 (2008).
  • Emonts M, Hazelzet JA, de Groot R, Hermans PW. Host genetic determinants of Neisseria meningitidis infections. Lancet Infect. Dis. 3(9), 565–577 (2003).
  • Imrey PB, Jackson LA, Ludwinski PH et al. Meningococcal carriage, alcohol consumption, and campus bar patronage in a serogroup C meningococcal disease outbreak. J. Clin. Microbiol. 33(12), 3133–3137 (1995).
  • Fischer M, Hedberg K, Cardosi P et al. Tobacco smoke as a risk factor for meningococcal disease. Pediatr. Infect. Dis. J. 16(10), 979–983 (1997).
  • Bruce MG, Rosenstein NE, Capparella JM, Shutt KA, Perkins BA, Collins M. Risk factors for meningococcal disease in college students. JAMA 286(6), 688–693 (2001).
  • Kriz P, Bobak M, Kriz B. Parental smoking, socioeconomic factors, and risk of invasive meningococcal disease in children: a population based case-control study. Arch. Dis. Child. 83(2), 117–121 (2000).
  • Campbell H, Borrow R, Salisbury D, Miller E. Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine 27(Suppl. 2), B20–B29 (2009).
  • Cano R, Larrauri A, Mateo S, Alcalá B, Salcedo C, Vázquez JA. Impact of the meningococcal C conjugate vaccine in Spain: an epidemiological and microbiological decision. Euro Surveill. 9(7), 11–15 (2004).
  • Trotter CL, Ramsay ME. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. FEMS Microbiol. Rev. 31(1), 101–107 (2007).
  • Booy R, Jelfs J, El Bashir H, Nissen MD. Impact of meningococcal C conjugate vaccine use in Australia. Med. J. Aust. 186(3), 108–109 (2007).
  • de Greeff SC, de Melker HE, Spanjaard L, Schouls LM, van Derende A. Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in The Netherlands. Pediatr. Infect. Dis. J. 25(1), 79–80 (2006).
  • Maiden MC, Stuart JM; UK Meningococcal Carriage Group. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 359(9320), 1829–1831 (2002).
  • Campbell H, Andrews N, Borrow R, Trotter C, Miller E. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin. Vaccine Immunol. 17(5), 840–847 (2010).
  • Kinlin LM, Jamieson F, Brown EM et al. Rapid identification of herd effects with the introduction of serogroup C meningococcal conjugate vaccine in Ontario, Canada, 2000–2006. Vaccine 27(11), 1735–1740 (2009).
  • Trotter CL, Borrow R, Findlow J et al. Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era. Clin. Vaccine Immunol. 15(11), 1694–1698 (2008).
  • LaForce FM, Konde K, Viviani S, Préziosi MP. The Meningitis Vaccine Project. Vaccine 25(Suppl. 1), A97–100 (2007).
  • Bilukha OO, Rosenstein N; National Center for Infectious Diseases, CDC. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. Recomm. Rep. 54(RR-7), 1–21 (2005).
  • Snape MD, Kelly DF, Salt P et al. Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization. Clin. Infect. Dis. 43(11), 1387–1394 (2006).
  • Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat. Rev. Immunol. 9(3), 213–220 (2009).
  • Ortega-Sanchez IR, Meltzer MI, Shepard C et al.; Active Bacterial Core Surveillance Team. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States. Clin. Infect. Dis. 46(1), 1–13 (2008).
  • Patel MS. Australia’s century of meningococcal disease: development and the changing ecology of an accidental pathogen. Med. J. Aust. 186(3), 136–141 (2007).
  • CDC. Recommendation of the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MenACWY-D) among children aged 9 through 23 months at increased risk for invasive meningococcal disease. Morbid. Mortal. Wkly Rep. 60, 1391–1392 (2011).
  • Kelly DF, Moxon ER, Pollard AJ. Haemophilus influenzae type B conjugate vaccines. Immunology 113(2), 163–174 (2004).
  • Díez-Domingo J, Cantarino MV, Torrentí JM et al.; MenC Study Group. A randomized, multicenter, open-label clinical trial to assess the immunogenicity of a meningococcal C vaccine booster dose administered to children aged 14 to 18 months. Pediatr. Infect. Dis. J. 29(2), 148–152 (2010).
  • Knuf M, Kieninger-Baum D, Habermehl P et al. A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children. Vaccine 28(3), 744–753 (2010).
  • Ostergaard L, Lebacq E, Poolman J, Maechler G, Boutriau D. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15–25 years. Vaccine 27(1), 161–168 (2009).
  • Frasch CE, Borrow R, Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine 27(Suppl. 2), B112–B116 (2009).
  • Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection–serum bactericidal antibody activity. Vaccine 23(17–18), 2222–2227 (2005).
  • Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin. Diagn. Lab. Immunol. 10(5), 780–786 (2003).
  • Pace D. Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy. Expert Rev. Vaccines 8(5), 529–542 (2009).
  • Trotter CL, Maiden MC. Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert Rev. Vaccines 8(7), 851–861 (2009).
  • Klein NP, Medford S, Malacaman E et al. Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy toddlers. Presented at: 48th Annual Meeting Infectious Disease Society of America. BC, Canada, 21–24 October 2010.
  • Vesikari T, Karvonen A, Lindblad N, Poolman J, Boutriau D. Immunogenicity of one dose of an investigational meningococcal tetravalent tetanus-toxoid conjugate (ACWY-TT) vaccine in 1–2 year-olds. Presented at: 27th Annual meeting of the European Society for Pediatric Infectious Diseases. Brussels, Belgium, 9–13 June 2009.
  • Vesikari T, Karvonen A, Bianco V, Van der Wielen M, Miller J. Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when coadministered with measles–mumps–rubella–varicella vaccine during the second year of life: an open, randomized controlled trial. Vaccine 29(25), 4274–4284 (2011).
  • Vesikari T, Karvonen A, Korhonen T, Poolman J, Boutriau D. Immunogenicity of one dose of an investigational meningococcal tetravalent tetanus-toxoid conjugate (ACWY-TT) vaccine in 2–10 year-olds. Presented at: 27th Annual meeting of the European Society for Pediatric Infectious Diseases. Brussels, Belgium, 9–13 June 2009.
  • Knuf M, Romain O, Krause K-H et al. The candidate MENACWY-TT conjugate vaccine is immunogenic and has an acceptable safety profile in children 2–10 years of age. Presented at: 28th Annual meeting of the European Society for Pediatric Infectious Diseases. Nice, France, 4–8 May 2010.
  • Memish ZA, Dbaibo G, Montellano M et al. Immunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135, and Y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed-ACWY polysaccharide vaccine with an acceptable safety profile. Pediatr. Infect. Dis. J. 30(4), e56–e62 (2011).
  • Bermal N, Huang LM, Dubey AP et al. Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults. Hum. Vaccin. 7(2), 239–247 (2011).
  • Borja-Tabora CM, Memish Z, Gatchalian S, Boutriau D, Van der Wielen M, Miller J. Immunogenicity of one dose of an investigational meningococcal tetravalent tetanus-toxoid conjugate (MENACWY-TT) vaccine in 11–17 years old. Presented at: 6th World Society of Pediatric Infectious Diseases. Buenos Aires, Argentina, 19–22 November 2009.
  • Baxter R, Baine Y, Ensor K, Bianco V, Friedland LR, Miller JM. Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age. Pediatr. Infect. Dis. J. 30(3), e41–e48 (2011).
  • Black S, Klein NP, Shah J, Bedell L, Karsten A, Dull PM. Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2–10 years of age. Vaccine 28(3), 657–663 (2010).
  • Jackson LA, Jacobson RM, Reisinger KS, Anemona A, Danzig LE, Dull PM. A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents. Pediatr. Infect. Dis. J. 28(2), 86–91 (2009).
  • Perrett KP, Snape MD, Ford KJ et al. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants. Pediatr. Infect. Dis. J. 28(3), 186–193 (2009).
  • Halperin SA, Gupta A, Jeanfreau R et al. Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2–10 years of age. Vaccine 28(50), 7865–7872 (2010).
  • Dbaibo G, Macalalad N, Aplasca-De Los Reyes MR et al. The immunogenicity of the candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (MENACWY-TT) is non-inferior to the licensed meningococcal tetravalent polysaccharide vaccine and has an acceptable safety profile in adults. Presented at: 3rd Northern European Conference on Travel Medicine. Hamburg, Germany, 26–29 May 2010.
  • Macalalad N, Aplasca-De Los Reyes MR, Dimaano E et al. The candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (MENACWY-TT) and the seasonal influenza virus vaccine are immunogenic and well-tolerated when coadministered in adults. Presented at: 3rd Northern European Conference on Travel Medicine. Hamburg, Germany, 26–29 May 2010.
  • Vesikari T, Karvonen A, Lindblad N et al. Immunogenicity of one dose of an investigational meningococcal tetravalent tetanus-toxoid conjugate (MENACWY-TT) vaccine in toddlers and children one year after vaccination. Presented at: 6th World Society of Pediatric Infectious Diseases. Buenos Aires, Argentina, 19–22 November 2009.
  • Knuf M, Prieler A, Poolman J, Vink P, Boutriau D. Antibody persistence and immune memory 15 months after meningococcal tetravalent tetanus-toxoid conjugate (ACWY-TT) vaccine in toddlers and 3–5 year-olds. Presented at: 27th Annual meeting of the European Society for Pediatric Infectious Diseases. Brussels, Belgium, 9–13 June 2009.
  • Østergaard L, Bianco V, Van der Wielen M, Miller J. Persistence of immune response to candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid-conjugated vaccine (MENACWY-TT) up to 42 months following primary vaccination. Presented at: 3rd Congress of the European Academy of Paediatric Societies. Copenhagen, Denmark, 23–26 October 2010.
  • Knuf M, Pantazi-Chatzikonstantinou A, Pfletschinger U et al. An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine coadministered with Infanrix hexa is immunogenic, with an acceptable safety profile in 12–23-month-old children. Vaccine 29(25), 4264–4273 (2011).
  • Vesikari T, Bianco V, Van der Wielen M, Miller J. Immunogenicity and Safety of the coadministration of the MenACWY-TT conjugate vaccine with MMRV in toddlers. Presented at: 28th Annual meeting of the European Society for Pediatric Infectious Diseases. Nice, France, 4–8 May 2010.
  • Ostergaard L, Silfverdal SA, Schade Larsen C et al. The candidate meningococcal serogroup A, C, W-135, Y conjugate vaccine (MENACWY-TT) coadministered with a combined hepatitis A and B vaccine (HEPPA/B) is immunogenic and well tolerated in subjects aged 11–17 years. Presented at: 3rd Northern European Conference on Travel Medicine. Hamburg, Germany, 26–29 May 2010.

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.